Reparixin is an antagonist of IL-8 that binds CXCR1 and CXCR2 receptors to prevent neutrophil chemotaxis, thus avoiding graft tissue damage in organ transplantation and cancer, including breast cancer (182, 183). Here, CXCL8 is linked to breast carcinoma.